Abstract: The present disclosure teaches an apparatus and a method for providing one or more substance liquids to a microfluidic channel network. The microfluidic apparatus includes valves for switching the one or more substance liquids to a microfluidic channel network. The apparatus can be used to generate a sequence of the one or more substance liquids as individual droplets in an immiscible separation liquid wherein individual ones of the sequence of droplets are located between the separation liquid.

Abstract: An apparatus and a method for providing one or more substance liquids to a microfluidic channel network (30). The microfluidic apparatus includes valves for switching the one or more substance liquids to a microfluidic channel network (30). The apparatus can be used to generate a sequence of the one or more substance liquids as individual droplets in an immiscible separation liquid wherein individual ones of the sequence of droplets are located between the separation liquid.

Abstract: An apparatus and a method for providing one or more substance liquids to a microfluidic channel network (30). The microfluidic apparatus includes valves for switching the one or more substance liquids to a microfluidic channel network (30). The apparatus can be used to generate a sequence of the one or more substance liquids as individual droplets in an immiscible separation liquid wherein individual ones of the sequence of droplets are located between the separation liquid.

Abstract: The present disclosure teaches an apparatus and a method for providing one or more substance liquids to a microfluidic channel network (30). The microfluidic apparatus includes valves for switching the one or more substance liquids to a microfluidic channel network (30). The apparatus can be used to generate a sequence of the one or more substance liquids as individual droplets in an immiscible separation liquid wherein individual ones of the sequence of droplets are located between the separation liquid.

Abstract: The present invention relates to unnatural amino acids comprising a cyclooctynyl or trans-cyclooctenyl analog group and having formula (I) or an acid or base addition salt thereof. The invention also relates to the use of said unnatural amino acids, kits and processes for preparation of polypeptides that comprise one or more than one cyclooctynyl or trans-cyclooctenyl analog group. These polypeptides can be covalently modified by in vitro or in vivo reaction with compounds comprising an azide, nitrile oxide, nitrone, diazocarbonyl or 1,2,4,5-tetrazine group.

Abstract: The present invention relates to unnatural amino acids comprising a cyclooctynyl or trans-cyclooctenyl analog group and having formula (I) or an acid or base addition salt thereof. The invention also relates to the use of said unnatural amino acids, kits and processes for preparation of polypeptides that comprise one or more than one cyclooctynyl or trans-cyclooctenyl analog group. These polypeptides can be covalently modified by in vitro or in vivo reaction with compounds comprising an azide, nitrile oxide, nitrone, diazocarbonyl or 1,2,4,5-tetrazine group.

Abstract: The present invention relates to crystals of phosphorylated Aurora-A kinase fragment alone and in complex with a ligand, amino acid residues 1-43 of human TPX2. This invention also relates to methods for designing and selecting ligands, in particular allosteric inhibitors of Aurora-A, that bind to the Aurora-A kinase and their use. Further, the present invention relates to certain indene and indole derivatives. The present invention relates to crystals of phosphorylated Aurora-A kinase alone and in complex with a ligand, amino acid residues 1-43 of human TPX2. This invention also relates to methods for designing and selecting ligands that bind to the Aurora-A kinase and their use. Further, the present invention relates to certain indene and indole derivative.